Sol Gel Technologies Ltd
NASDAQ:SLGL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (9.2), the stock would be worth $64.22 (17% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 11.1 | $77 |
0%
|
| 3-Year Average | 9.2 | $64.22 |
-17%
|
| 5-Year Average | 9.2 | $64.22 |
-17%
|
| Industry Average | 2.2 | $15.05 |
-80%
|
| Country Average | 2.5 | $17.45 |
-77%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$207.1m
|
/ |
Jan 2026
$19.4m
|
= |
|
|
$207.1m
|
/ |
Dec 2026
$5.4m
|
= |
|
|
$207.1m
|
/ |
Dec 2027
$17.4m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| IL |
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
250.3m USD | 11.1 | -35 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
820.3B USD | 12.6 | 39.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
542.6B USD | 5.6 | 25.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.7B GBP | 4.9 | 28.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.2B CHF | 4.9 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.8B USD | 4.2 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 3.8 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.3B USD | 2.4 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 2.4 | 16.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.3 |
| Median | 2.5 |
| 70th Percentile | 5 |
| Max | 2 738.9 |
Other Multiples
Sol Gel Technologies Ltd
Glance View
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
